Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Given Consensus Rating of “Buy” by Analysts
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has earned a consensus recommendation of “Buy” from the twenty-one brokerages that are covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, thirteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $183.51.
ICPT has been the topic of several research reports. Oppenheimer Holdings, Inc. reissued an “outperform” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, April 12th. Cowen and Company restated a “buy” rating and issued a $225.00 target price on shares of Intercept Pharmaceuticals in a research note on Monday, April 24th. Zacks Investment Research cut shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. Cantor Fitzgerald set a $60.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “sell” rating in a research note on Thursday, May 4th. Finally, Laidlaw upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $115.00 target price for the company in a research note on Friday, May 5th.
In other Intercept Pharmaceuticals news, CMO David Shapiro sold 1,117 shares of the firm’s stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $112.18, for a total transaction of $125,305.06. Following the completion of the transaction, the chief marketing officer now directly owns 46,582 shares in the company, valued at approximately $5,225,568.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel G. Welch sold 217 shares of the firm’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $126.76, for a total transaction of $27,506.92. Following the transaction, the director now owns 3,710 shares of the company’s stock, valued at $470,279.60. The disclosure for this sale can be found here. Insiders sold 47,240 shares of company stock valued at $6,091,919 in the last quarter. Company insiders own 4.50% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares during the period. US Bancorp DE acquired a new position in Intercept Pharmaceuticals during the first quarter valued at $130,000. Quantbot Technologies LP acquired a new position in Intercept Pharmaceuticals during the first quarter valued at $170,000. Pacer Advisors Inc. increased its position in Intercept Pharmaceuticals by 21.6% in the first quarter. Pacer Advisors Inc. now owns 1,861 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 330 shares during the period. Finally, Aperio Group LLC acquired a new position in Intercept Pharmaceuticals during the second quarter valued at $212,000. Hedge funds and other institutional investors own 84.24% of the company’s stock.
Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 127.40 on Monday. The company’s 50-day moving average is $123.24 and its 200-day moving average is $117.13. Intercept Pharmaceuticals has a 52-week low of $96.63 and a 52-week high of $177.93. The firm’s market capitalization is $3.19 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($3.61) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($4.27) by $0.66. Intercept Pharmaceuticals had a negative net margin of 825.58% and a negative return on equity of 116.30%. The company had revenue of $21 million for the quarter, compared to the consensus estimate of $15.88 million. During the same period last year, the firm posted ($5.17) EPS. Intercept Pharmaceuticals’s revenue for the quarter was up 4566.7% on a year-over-year basis. On average, analysts predict that Intercept Pharmaceuticals will post ($14.40) EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/07/24/intercept-pharmaceuticals-inc-nasdaqicpt-given-consensus-rating-of-buy-by-analysts.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.